Idiopathic Pulmonary Fibrosis Treatment Market Growth, Demand and Challenges of the Key Industry Players

1
Global Idiopathic Pulmonary Fibrosis Treatment
Market Research and Forecast Report 2022-2027




Author Elena Anderson Marketing Manager IMARC
Group
2022 IMARC All Rights Reserved
Copyright IMARC Service Pvt Ltd. All Rights
Reserved
2
About IMARC Group
Report Description
International Market Analysis Research and
Consulting Group is a leading adviser on
management strategy and market research
worldwide. We partner with clients in all regions
and industry verticals to identify their
highest-value opportunities, address their most
critical challenges, and transform their
businesses. IMARCs information products include
major market, scientific, economic and
technological developments for business leaders
in pharmaceutical, industrial, and high
technology organizations. Market forecasts and
industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel
and tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Global Idiopathic Pulmonary Fibrosis Treatment
Market Research Report 2022-2027 The latest
report by IMARC Group, titled Idiopathic
Pulmonary Fibrosis Treatment Market Global
Industry Trends, Share, Size, Growth, Opportunity
and Forecast 2022-2027, finds that the global
idiopathic pulmonary fibrosis treatment market
reached a value of US 3,278 Million in 2021.
Idiopathic pulmonary fibrosis (IPF) is an
interstitial lung disease that causes scarring of
the lungs, reducing their oxygen delivering
capacity. The chronic lung disease is progressive
and irreversible in nature as it continuously
impacts the functioning of the lungs. It causes
difficulty in breathing and does not provide
sufficient oxygen to different body parts. IPF
can be diagnosed through chest imaging studies,
lung biopsies, pulmonary function tests, and
antibody tests. Thetreatment includes
nintedanib and pirfenidone-based drugs that aid
in lung functioning and minimize the risk of
acute respiratory deterioration. They are also
offered along with oxygen therapy and palliative
care, which improve the chances of recovery and
provide comfort to the patient. Request for a
PDF sample of this report https//www.imarcgroup.
com/idiopathic-pulmonary-fibrosis-treatment-market
/requestsample

4
Report Description and Highlights
Report Description
Global Idiopathic Pulmonary Fibrosis Treatment
Market Trends The market is primarily driven by
the rising geriatric population,which is
susceptible tolung disorders. Aging is considered
the greatest risk factor for the development of
IPF. Moreover, the growing prevalence of fibrotic
diseases, owing to changing lifestyles and heavy
consumption of nicotine products like cigarettes
is also propelling the demand for IPF treatment.
Besides this, major healthcare companies are
extensively investing in the development and
commercialization of novel drugs, especially in
emerging economies, which is fueling the growth
of the market. The rising health consciousness
among individuals regarding effective management
strategies is also creating a positive outlook
for the market. Furthermore, increasing
healthcare expenditures and improving
infrastructure arealso facilitating the market
growth. Looking forward, the market value is
expected to reach US 5,268 Million by 2027,
exhibiting a CAGR of 7.89 during the forecast
period (2022-2027). View Report TOC, Figures and
Tables https//www.imarcgroup.com/idiopathic-pulm
onary-fibrosis-treatment-market

5
Report Description and Highlights
Report Description

• Key Market Segmentation
• The research report includes the following
  segments
• Breakup by Drug Class
• MAPK Inhibitors
• Tyrosine Inhibitors
• Autotaxin Inhibitors
•  
• Breakup by End User
• Hospitals
• Long-term Care Facilities
• Others
• Breakup by Region
• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa

6
Report Description and Highlights
Report Description

•  
• Competitive Landscape with Key Players
• AdAlta Pty Ltd.
• Angion Biomedica Corp.
• Boehringer Ingelheim International GmbH (C. H.
  Boehringer Sohn AG Co. KG)
• Bristol-Myers Squibb Company
• Cipla Inc.
• F. Hoffmann-La Roche AG (Roche Holding AG)
• Fibrogen Inc.
• Galapagos NV, Liminal BioSciences Inc.
• Medicinova Inc.
• Merck Co. Inc.
• Novartis AG
• Vectura Group Plc.
•  

7
Key Questions Answered in the Report
Report Description

• How has the global idiopathic pulmonary fibrosis
  treatment market performed so far and how will it
  perform in the coming years?
• What has been the impact of COVID-19 on the
  global idiopathic pulmonary fibrosis treatment
  market?
• What are the key regional markets?
• What is the breakup of the market based on the
  drug class?
• What is the breakup of the market based on the
  end user?
• What are the various stages in the value chain of
  the industry?
• What are the key driving factors and challenges
  in the industry?
• What is the structure of the global idiopathic
  pulmonary fibrosis treatment market and who are
  the key players?
• What is the degree of competition in the
  industry?
•  

8
Table of Contents
Report Description
1    Preface2    Scope and Methodology     2.1
   Objectives of the Study    2.2  
 Stakeholders    2.3    Data Sources       
2.3.1    Primary Sources        2.3.2  
 Secondary Sources    2.4    Market Estimation 
      2.4.1    Bottom-Up Approach        2.4.2  
 Top-Down Approach    2.5    Forecasting
Methodology3    Executive Summary4  
 Introduction    4.1    Overview    4.2    Key
Industry Trends5    Global Idiopathic Pulmonary
Fibrosis Treatment Market    5.1    Market
Overview    5.2    Market Performance    5.3  
 Impact of COVID-19    5.4    Market Forecast

9
Table of Contents
Report Description
6    Market Breakup by Drug Class    6.1  
 MAPK Inhibitors        6.1.1 Market Trends   
    6.1.2 Market Forecast    6.2    Tyrosine
Inhibitors        6.2.1 Market Trends       
6.2.2 Market Forecast    6.3    Autotaxin
Inhibitors        6.3.1 Market Trends       
6.3.2 Market Forecast7    Market Breakup by End
User    7.1    Hospitals        7.1.1 Market
Trends        7.1.2 Market Forecast    7.2  
 Long-term Care Facilities        7.2.1 Market
Trends          Click here to visit the
complete table of content with list of figures
and tables https//www.imarcgroup.com/idiopathic-
pulmonary-fibrosis-treatment-market/toc

10
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
11
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
12
Report Description and Highlights
Report Description

2022 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
13

Contact Us